Evaluation of Pharmacokinetic and Safety of NVP-2102 and NVP-2102-R in Healthy Subjects

A Phase 1 Clinical Trial, Open-label, Randomized Study in Healthy Subjects to Evaluate Pharmacokinetic Characteristics and Safety After Oral Administration of NVP-2102 and NVP-2102-R in Healthy Subjects

The purpose of this study is to compare the pharmacokinetics and safety of NVP-2102 and NVP-2102-R.

Evaluate the pharmacokinetics and safety of NVP-2102 compared to NVP-2102-R

Inclusion Criteria:

• Healthy subject, 19 years of age or older
• Subjects who signed informed consent
• Body mass index(BMI) of 18 to 30.0 kg/㎡

Exclusion Criteria:

• Subject who has clinically significant medical history
• Inadequate subject for the clinical trial by the investigator's decision
• Subjects participated in another clinical trial within 6 months prior to the first administration of investigational product